Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
IPO Year: 2021
Exchange: NASDAQ
Website: senseibio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/2/2025 | $5.00 | Buy | H.C. Wainwright |
| 5/14/2024 | $5.00 | Overweight | Stephens |
| 3/10/2022 | $12.00 → $10.00 | Overweight | Piper Sandler |
| 7/1/2021 | $12.00 | Buy → Hold | Berenberg |
| 6/29/2021 | $30.00 → $14.00 | Outperform → Perform | Oppenheimer |
| 6/29/2021 | Outperform → Perform | Oppenheimer |
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
DEF 14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
Fastest customizable press release news feed in the world
6-month progression-free survival (PFS) of 50% in the higher 15 mg/kg dose cohort compares favorably to historical PD-(L)1 refractory settings –All clinical responses, including a complete response, observed in the higher 15 mg/kg dose cohort –Favorable safety profile with six cases of mild, manageable grade 1 cytokine release syndrome (CRS) across all patients treated to date, all of which occurred in the 15 mg/kg dose cohort –Data support advancement to Phase 2 studies, currently being planned in Non-Small Cell Lung Cancer and Merkel Cell Carcinoma –Sensei to host investor webcast Monday, October 20th at 8:00 AM ET – BOSTON, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc.
BOSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will host a virtual key opinion leader (KOL) event on Monday, October 20, 2025 at 8:00 AM ET featuring company leadership and Kyriakos Papadopoulos, MD (Co-Director of Clinical Research at START, San Antonio), who will discuss the unmet need and current treatment landscape for immunotherapy-resistant solid tumors. To register, click here. The event will provide an update on the Company's plans for Phase 2 studies and data from the full Phase 1/2 dos
BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025. An on-demand corporate presentation will be available here on September 5, 2025, at 7:00 a.m. ET. A replay of the webcast will be available in the Investors section of the Sensei website for approximately 90 days following the event. About Sensei Biotherapeutics Sens
- Full data for Phase 1/2 dose expansion cohort expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, Aug. 05, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter 2025, and provided a corporate update. "The second quarter was a key inflection point for Sensei, as we now transition from early response-focused readouts to longer-term and commercially relevant efficacy signals with the maturity of the data from our Phase 1/2 stu
BOSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, announced today that clinical data from the dose expansion cohort of the Phase 1/2 trial of solnerstotug alone and in combination with Libtayo® (cemiplimab), Regeneron's PD-1 inhibitor, will be presented in a mini oral session at the European Society for Medical Oncology (ESMO) Congress 2025, being held October 17-21, 2025 in Berlin, Germany. Presentation Details: Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined
BOSTON, June 13, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that it will implement a 1-for-20 reverse stock split of its issued and outstanding shares of common stock ("Reverse Stock Split"), effective at 5:00 p.m. Eastern Time on June 16, 2025. The Reverse Stock Split was approved by the Company's stockholders at the Company's Annual Meeting of Stockholders held on May 21, 2025, with the final ratio subsequently determined by the Company's Board of Directors. The reverse stock split is intended to bring the Company i
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. "This was a breakthrough quarter for Sensei," said John Celebi, President and CEO. "We observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers from our dose expansi
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tum
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2024, and
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 resistant "hot" tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time – – Sensei to host investor webcast today at 5:30 p.m. ET – BOSTON, March
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
H.C. Wainwright resumed coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $5.00
Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00
Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously
Berenberg downgraded Sensei Biotherapeutics from Buy to Hold and set a new price target of $12.00
Oppenheimer downgraded Sensei Biotherapeutics from Outperform to Perform and set a new price target of $14.00 from $30.00 previously
Oppenheimer downgraded Sensei Biotherapeutics from Outperform to Perform
Piper Sandler initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $25.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform
Live finance-specific insights
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA candidate and initiate IND-enabling studies by year-end 2021 - SNS-401-NG on track to start IND-enabling studies in second half of 2022 – -Strong cash position of $162.5 million to support platform innovation and next generation program development - BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reporte
Live Leadership Updates
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escalation study now expected in Q2 2024, ahead of previous guidance - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full ye
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new clinical data milestones anticipated throughout 2024 - - Strong balance sheet with cash runway into the second half of 2025 - BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third qua
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer. Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company's growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners. Prior to this, she held business and corporate development roles of increasing responsibility i
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer. "Patrick is an accomplished biotech executive who brings significant strategic and transactional expertise to Sensei. He has worked across the biotechnology, Big Pharma, venture and banking sectors and has a track record of tailoring partnerships and transactions to build value," said John Celebi, president and chief executive officer of Sensei Biotherapeutics. "We're thrilled to add him to our leadership
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of 2025 with $136.2 million on hand at end of first quarter 2022 - BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates. "We continue to make significant progress in the development of our TMAb™ platform, which is designed to address the chall
BOSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of William (Bill) Ringo, MBA, as chair of its Board of Directors. "Bill is an accomplished life sciences leader who has been instrumental to the success of multiple pharmaceutical companies and biotechs. His experience and insights will be invaluable to us as we advance our business objectives and pipeline of potentially transformative oncology therapeutics," said John Celebi, president and chief executive officer of Sensei Biotherapeutics. "We're delighted to hav
BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D., Professor of Medicine, Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and Richard Ulevitch, Ph.D., Professor of Immunology and Chairman Emeritus at The Scripps Research Institute, to its Immuno-Oncology Advisory Board. "We are honored to welcome both Dr. Gillison and Dr. Ulevitch to our Immuno-Oncology Advisory Board, two astounding leaders in the field of oncology and immuno
This live feed shows all institutional transactions in real time.
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)